Teva Pharmaceuticals' Response to European Commission Ruling
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA, TASE: TEVA.TA) has recently expressed its firm opposition to a decision made by the European Commission. The company believes the foundations of this decision are based on legal theories that are extreme, untested, and not supported by factual evidence. Teva's commitment to its core values clings strongly to integrity, and it will not let this situation impede its mission to provide essential healthcare to patients in need.
Legal Standpoint and Appeal Plans
The company intends to appeal the judgement and the accompanying fine imposed by the Commission. Teva is fully prepared to mount a robust defense as it believes that the accusations and conclusions drawn by the European Commission lack substantial validation. Since 2019, Teva has been cooperative in the Commission's investigations and vehemently disagrees with the interpretations made regarding its practices surrounding COPAXONE, a leading treatment for multiple sclerosis (MS).
The Importance of COPAXONE in MS Treatment
COPAXONE has served as a vital standard-of-care treatment for individuals coping with multiple sclerosis for many years. Teva has prioritized support for the MS community since 1996, dedicating itself to ensuring that patients and their families have access to this important therapeutic option. This dedication will not waver in light of unfavorable decisions.
Commitment to Ethical Standards
Operating within the highly regulated pharmacological industry, Teva Pharmaceuticals maintains rigorous ethical standards in all of its collaborations with external experts. The company remains steadfast in its stance that it conducts its business activities lawfully and sincerely. Teva's integrity as a partner to Europe extends beyond just compliance with regulations; it entails a commitment to patients, the economy, and the overall healthcare system.
Support for Patients and Communities
Despite the recent challenges posed by the Commission's decision, Teva is more determined than ever to advocate for patients living with MS. The company fully recognizes the struggles these patients and their families face daily and strives to ensure that necessary treatments remain accessible and affordable. Teva's focus remains unwavering on supporting the healthcare community during this pivotal time.
Media Contacts for Further Information
For inquiries regarding this decision and its implications, the media can reach out to:
Kelley Dougherty at (973) 832-2810
Eden Klein at +972 (3) 906 2645
Frequently Asked Questions
What is the main reason Teva is appealing the European Commission's decision?
Teva disagrees with the Commission's legal theories, which it finds extreme and untested, prompting its decision to appeal.
How has Teva supported MS patients?
Teva has been committed to supporting the MS community since 1996, providing access to COPAXONE as an important treatment option.
What steps will Teva take following the Commission's ruling?
Teva plans to vigorously defend its position through legal appeal and has expressed readiness to mount a strong defense.
In what areas does Teva maintain ethical standards?
Teva works with external experts and conducts its business within a highly regulated environment, maintaining high ethical standards throughout.
Who can media representatives contact for more information?
Media can reach out to Kelley Dougherty or Eden Klein for further inquiries related to the company and the recent decision.
